Replimune Group, Inc. reported earnings results for the full year ended March 31, 2023. For the full year, the company reported net loss was USD 174.28 million compared to USD 118.04 million a year ago. Basic loss per share from continuing operations was USD 2.99 compared to USD 2.26 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.23 USD | -7.60% | -11.95% | -37.96% |
05-16 | Replimune Group, Inc. Reports Earnings Results for the Full Year Ended March 31, 2024 | CI |
04-08 | Replimune Group Provides Interim Results for Skin Cancer Therapy | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-37.96% | 321M | |
+67.53% | 63.85B | |
-0.77% | 41.83B | |
+42.78% | 40.47B | |
-10.02% | 27.17B | |
+13.30% | 26.52B | |
-22.79% | 18.69B | |
+4.70% | 12.73B | |
+24.10% | 12.11B | |
+27.41% | 12.07B |
- Stock Market
- Equities
- REPL Stock
- News Replimune Group, Inc.
- Replimune Group, Inc. Reports Earnings Results for the Full Year Ended March 31, 2023